- Record: found
- Abstract: not found
- Article: not found
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Jonathan R Strosberg ,
Martyn E Caplin ,
Pamela L Kunz ,
Philippe B Ruszniewski ,
Lisa Bodei ,
Andrew Hendifar ,
Erik Mittra ,
Edward M Wolin ,
James C Yao ,
Marianne E Pavel ,
Enrique Grande ,
Eric Van Cutsem ,
Ettore Seregni ,
Hugo Duarte ,
Germo Gericke ,
Amy Bartalotta ,
Maurizio F Mariani ,
Arnaud Demange ,
Sakir Mutevelic ,
Eric P Krenning
November 2021
November 2021
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d3575648e339">The primary analysis of the phase 3 NETTER-1 trial
showed significant improvement
in progression-free survival with 177Lu-Dotatate plus long-acting octreotide versus
high-dose long-acting octreotide alone in patients with advanced midgut neuroendocrine
tumours. Here, we report the prespecified final analysis of overall survival and long-term
safety results.
</p>